What is Capsida?
Founded in 2019, Capsida Biotherapeutics Inc. operates at the intersection of synthetic biology and clinical medicine. The company specializes in the creation of next-generation gene therapies designed to overcome the limitations of traditional viral vectors. Through its biologically driven, high-throughput AAV engineering platform, Capsida is capable of identifying and optimizing capsids that exhibit superior tissue tropism. This technological edge allows for the development of therapies that can precisely target specific organs while minimizing off-target effects, a critical requirement for the safety and efficacy of systemic gene delivery. As a key player in the biotechnology sector, Capsida is strategically positioned to address significant unmet medical needs in neurology and other therapeutic areas where traditional modalities have historically struggled to achieve therapeutic thresholds.
How much funding has Capsida raised?
Capsida has raised a total of $140M across 2 funding rounds:
Corporate Investment
$90M
Series A
$50M
Corporate Investment (2021): $90M with participation from AbbVie
Series A (2021): $50M led by Westlake Village BioPartners and Versant Ventures
Key Investors in Capsida
AbbVie
A global biopharmaceutical leader focused on immunology, oncology, and neuroscience, dedicated to delivering innovative medicines for complex medical challenges.
Westlake Village BioPartners
A life science venture capital firm that incubates and supports early-stage biotech companies, emphasizing hands-on guidance to transform scientific breakthroughs into patient treatments.
Versant Ventures
A premier global venture capital firm with a strong track record in building innovative biotechnology companies through extensive scientific expertise and multi-disciplinary laboratory support.
What's next for Capsida?
With the recent infusion of capital, Capsida is poised to transition from a research-focused entity into a clinical-stage powerhouse. The strategic roadmap involves expanding its internal laboratory capabilities and deepening its collaborative efforts with established pharmaceutical partners. Investors are closely monitoring the company's ability to translate its AAV engineering breakthroughs into human clinical trials, which will serve as the ultimate validation of its platform's scalability. As the firm continues to refine its cargo development pipeline, the focus will likely shift toward securing additional intellectual property and establishing manufacturing partnerships to support future commercialization efforts. The current funding environment provides the necessary runway for Capsida to solidify its market position as a leader in the gene therapy space, potentially attracting further interest from institutional investors and strategic acquirers looking to bolster their portfolios with high-value, tissue-targeted assets.
See full Capsida company page
